An Adelaide hospital has signed up to a trial to evaluate the safety and functionality of the ARTO system implantation procedure.
St Andrews’s Hospital will be one of four hospitals involved in the MAVERIC trial to analyse the new minimally invasive procedure for heart patients who are not candidates for traditional surgeries.
St Andrew’s Hospital, Cardiologist Professor Stephen Worthley is one of the cardiologists leading the trial.
“The ARTO system provides a treatment for patients with congestive heart failure who are not candidates for the traditional open-heart surgical mitral valve repair,” said Professor Worthley.
Mitral regurgitation is a condition where the damaged mitral valve, fails to close tightly each time the heart contracts, resulting in regurgitation or “backward” flow of the blood to the atrium. So the heart must work harder to pump the extra blood and can lead to congestive heart failure.
The ARTO system is designed to reshape and tighten the mitral valve, enabling the “forward” flow of blood and alleviating mitral valve regurgitation.
This procedure will reduce symptoms of heart failure, such as shortness of breath and fatigue and improve overall quality of life.
The MAVERIC trial will enrol 30 patients in Australia, at four hospitals, of which about 10 patients from St Andrew’s Hospital.
St Andrew’s Hospital Director Nursing and Clinical Services, Jacquie Wiley is excited for the trial to start at the hospital.
“This global trial will positively impact a group of patients who would otherwise have limited options for treatment to alleviate symptoms which impact their daily lives,” said Ms Wiley.